search
Back to results

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Bexagliflozin
Placebo
Sponsored by
Theracos
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Each subject was required to meet the following criteria at the time of enrollment to be eligible for the study:

  1. To have been male or non-pregnant female ≥ 20 years of age. Women of childbearing potential were required to agree to use contraception throughout the study to avoid any possible pregnancy. Females who were surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses for greater than 12 months and age > 45 years) were eligible if they tested negative on the urine pregnancy test.
  2. To have had a diagnosis of T2DM with an HbA1c between 7.0 and 10.5% (inclusive) at the time of screening.
  3. To have been treatment naïve or to have been treated with a stable regimen of anti-diabetic medications. At the time of screening, the doses and frequency of all anti-diabetic medications were to have been stable for 8 weeks.
  4. To have had an eGFR ≥ 30 and < 60 mL min-1 per 1.73 m2 at 2 time points: screening (V1), and 1 additional time point between 1 and 12 months of screening (may be obtained from available medical records). The eGFR was calculated by the MDRD equation.
  5. To have had a body mass index (BMI) ≤ 45 kg per m2 (inclusive).
  6. To have been taking stable doses of medications for hypertension or hyperlipidemia (if applicable) for at least 30 days prior to randomization
  7. To have had stable eGFR between the historic value and day of screening (no more than 20% change in eGFR between the most recent historical value and the value determined at the screening visit V1).

9.3.2 Exclusion Criteria

Potential participants who exhibited any of the following characteristics were excluded from the study:

  1. A diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young (MODY)
  2. A hemoglobinopathy that could affect HbA1c measurement
  3. Frequent symptomatic hypoglycemia (greater than one episode per week on average)
  4. A history of genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months
  5. A cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix were not grounds for exclusion)
  6. A history of alcohol or illicit drug abuse in the past 2 years
  7. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
  8. A history of MI, stroke or hospitalization for heart failure, or hospitalization for unstable angina in the prior 3 months
  9. Evidence of NYHA class IV heart failure at screening or randomization
  10. A history of taking an SGLT2 inhibitor within 3 months of screening
  11. Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment
  12. A current status of pregnancy or breastfeeding
  13. A current status of renal replacement therapy (peritoneal or hemodialysis) or a history of renal transplantation
  14. A corrected serum calcium < 8 mg dL-1 at screening (V1) or randomization (V3)
  15. Uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >110 mm Hg)
  16. Participation in another interventional trial or exposure to an investigational drug within 30 days or 7 half-lives of screening, whichever was longer
  17. Previous exposure to bexagliflozin or EGT0001474
  18. Evidence of having skipped dosing more than once during the run-in period
  19. A fasting blood glucose value during the run-in period ≥ 250 mg dL-1 (13.9 mmol L-1) associated with severe clinical signs or symptoms of hyperglycemia
  20. Any episode of symptomatic hypoglycemia during the run-in period in which symptoms were severe
  21. An inability to comprehend or unwillingness to provide written informed consent in accordance with institutional and regulatory guidelines

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Bexagliflozin tablets, 20 mg

Placebo tablets

Arm Description

Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.

Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.

Outcomes

Primary Outcome Measures

Change From Baseline in HbA1c at 24 Weeks
The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with moderate renal impairment.

Secondary Outcome Measures

Change in Body Weight From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in BMI from baseline to week 24 in subjects with a BMI ≥ 25 kg/m2.
Change From Baseline in Systolic Blood Pressure (SBP) in Subjects With Baseline SBP ≥ 130 mm Hg at Week 24
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change from baseline in SBP to in subjects with baseline SBP ≥ 130 mm Hg at Week 24.
Change From Baseline in HbA1c in Subjects With Stage 3a CKD (eGFR 45 to 59 mL/Min/1.73 m2) at Week 24
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3a CKD (eGFR 45 to 59 mL/min/1.73 m2) at week 24.
Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3b CKD (eGFR 30 to 44 mL/min/1.73 m2) at week 24.

Full Information

First Posted
July 14, 2016
Last Updated
June 28, 2021
Sponsor
Theracos
search

1. Study Identification

Unique Protocol Identification Number
NCT02836873
Brief Title
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
Official Title
A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
September 23, 2016 (Actual)
Primary Completion Date
January 11, 2018 (Actual)
Study Completion Date
January 11, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theracos

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.
Detailed Description
The phase 3, double-blind, placebo-controlled parallel-group study was conducted at investigative sites in the US, Japan, France and Spain. Approximately 300 subjects were to be randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in equal ratio for 24 weeks. The study was to enrolled male and female participants who had T2DM with an HbA1c between 7.0 and 10.5% (inclusive) and stage 3 chronic kidney disease (CKD) as defined by an eGFR of ≥ 30 and< 60 mL min-1 per 1.73 m2 at the screening visit and one additional time of measurement between 1 and 12 months prior to screening. Subjects were either treatment naïve or were treated with a stable regimen of anti-diabetic medications. All eligible subjects were to enter a one-week single-blind, placebo run-in period. Subjects who were compliant in taking run-in medication, had screening eGFR ≥ 30 and< 60 mL min-1 per 1.73 m2, and had stable GFR (no more than 20% change in eGFR between a historical value and the value determined at the screening visit) were eligible for randomization. Randomization was stratified by HbA1c level (7.0 to 8.5% or 8.6 to 10.5%), anti-diabetic treatment regimen and eGFR (30 - 44 mL min-1 per 1.73 m2 or 45 - 59 mL min-1 per 1.73 m2). At least 135 subjects in each of the eGFR groups were planned. Study subjects were to schedule clinic visits at weeks 2, 6, 12, 18, and 24 for safety and efficacy evaluation. At weeks 2 and 18, the visits were to be conducted via phone interviews unless an in-person visit was considered clinically advisable. A final follow-up visit was to be conducted at week 26 or two weeks after the last dose of investigational product if the subject withdrew prior to week 24.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
312 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bexagliflozin tablets, 20 mg
Arm Type
Active Comparator
Arm Description
Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
Arm Title
Placebo tablets
Arm Type
Placebo Comparator
Arm Description
Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
Intervention Type
Drug
Intervention Name(s)
Bexagliflozin
Other Intervention Name(s)
EGT0001442, EGT0001474
Intervention Description
Bexagliflozin tablet, 20 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo (inactive) tablet to match the active comparator
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c at 24 Weeks
Description
The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with moderate renal impairment.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Change in Body Weight From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2
Description
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in BMI from baseline to week 24 in subjects with a BMI ≥ 25 kg/m2.
Time Frame
24 weeks
Title
Change From Baseline in Systolic Blood Pressure (SBP) in Subjects With Baseline SBP ≥ 130 mm Hg at Week 24
Description
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change from baseline in SBP to in subjects with baseline SBP ≥ 130 mm Hg at Week 24.
Time Frame
24 weeks
Title
Change From Baseline in HbA1c in Subjects With Stage 3a CKD (eGFR 45 to 59 mL/Min/1.73 m2) at Week 24
Description
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3a CKD (eGFR 45 to 59 mL/min/1.73 m2) at week 24.
Time Frame
24 weeks
Title
Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24
Description
A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3b CKD (eGFR 30 to 44 mL/min/1.73 m2) at week 24.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Each subject was required to meet the following criteria at the time of enrollment to be eligible for the study: To have been male or non-pregnant female ≥ 20 years of age. Women of childbearing potential were required to agree to use contraception throughout the study to avoid any possible pregnancy. Females who were surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses for greater than 12 months and age > 45 years) were eligible if they tested negative on the urine pregnancy test. To have had a diagnosis of T2DM with an HbA1c between 7.0 and 10.5% (inclusive) at the time of screening. To have been treatment naïve or to have been treated with a stable regimen of anti-diabetic medications. At the time of screening, the doses and frequency of all anti-diabetic medications were to have been stable for 8 weeks. To have had an eGFR ≥ 30 and < 60 mL min-1 per 1.73 m2 at 2 time points: screening (V1), and 1 additional time point between 1 and 12 months of screening (may be obtained from available medical records). The eGFR was calculated by the MDRD equation. To have had a body mass index (BMI) ≤ 45 kg per m2 (inclusive). To have been taking stable doses of medications for hypertension or hyperlipidemia (if applicable) for at least 30 days prior to randomization To have had stable eGFR between the historic value and day of screening (no more than 20% change in eGFR between the most recent historical value and the value determined at the screening visit V1). 9.3.2 Exclusion Criteria Potential participants who exhibited any of the following characteristics were excluded from the study: A diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young (MODY) A hemoglobinopathy that could affect HbA1c measurement Frequent symptomatic hypoglycemia (greater than one episode per week on average) A history of genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months A cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix were not grounds for exclusion) A history of alcohol or illicit drug abuse in the past 2 years Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN A history of MI, stroke or hospitalization for heart failure, or hospitalization for unstable angina in the prior 3 months Evidence of NYHA class IV heart failure at screening or randomization A history of taking an SGLT2 inhibitor within 3 months of screening Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment A current status of pregnancy or breastfeeding A current status of renal replacement therapy (peritoneal or hemodialysis) or a history of renal transplantation A corrected serum calcium < 8 mg dL-1 at screening (V1) or randomization (V3) Uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >110 mm Hg) Participation in another interventional trial or exposure to an investigational drug within 30 days or 7 half-lives of screening, whichever was longer Previous exposure to bexagliflozin or EGT0001474 Evidence of having skipped dosing more than once during the run-in period A fasting blood glucose value during the run-in period ≥ 250 mg dL-1 (13.9 mmol L-1) associated with severe clinical signs or symptoms of hyperglycemia Any episode of symptomatic hypoglycemia during the run-in period in which symptoms were severe An inability to comprehend or unwillingness to provide written informed consent in accordance with institutional and regulatory guidelines
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Allegretti, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Fresno
State/Province
California
ZIP/Postal Code
93720
Country
United States
Facility Name
Research Site
City
La Palma
State/Province
California
ZIP/Postal Code
90623
Country
United States
Facility Name
Research Site
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
Research Site
City
Riverside
State/Province
California
ZIP/Postal Code
92505
Country
United States
Facility Name
Research Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Research Site
City
San Dimas
State/Province
California
ZIP/Postal Code
91773
Country
United States
Facility Name
Research Site
City
Monument
State/Province
Colorado
ZIP/Postal Code
80132
Country
United States
Facility Name
Research Site
City
Norwalk
State/Province
Connecticut
ZIP/Postal Code
06851
Country
United States
Facility Name
Research Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Research Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Facility Name
Research Site
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Research Site
City
Paducah
State/Province
Kentucky
ZIP/Postal Code
42003
Country
United States
Facility Name
Research Site
City
Auburn
State/Province
Maine
ZIP/Postal Code
04210
Country
United States
Facility Name
Research Site
City
Rockport
State/Province
Maine
ZIP/Postal Code
04856
Country
United States
Facility Name
Research Site
City
Nashua
State/Province
New Hampshire
ZIP/Postal Code
03063
Country
United States
Facility Name
Research Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Research Site
City
Stow
State/Province
Ohio
ZIP/Postal Code
44224
Country
United States
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
Facility Name
Research Site
City
North Richland Hills
State/Province
Texas
ZIP/Postal Code
76180
Country
United States
Facility Name
Research Site
City
Round Rock
State/Province
Texas
ZIP/Postal Code
78681
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Research Site
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Research Site
City
Paris
ZIP/Postal Code
75877
Country
France
Facility Name
Research Site
City
Pierre Benite
ZIP/Postal Code
69310
Country
France
Facility Name
Research Site
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
Research Site
City
Venissieux
ZIP/Postal Code
69200
Country
France
Facility Name
Research Site
City
Atsugi-shi
State/Province
Kanagawa
ZIP/Postal Code
243-0035
Country
Japan
Facility Name
Research Site
City
Kamakura-shi
State/Province
Kanagawa
ZIP/Postal Code
247-0056
Country
Japan
Facility Name
Research Site
City
Kawasaki-shi
State/Province
Kanagawa
ZIP/Postal Code
210-0852
Country
Japan
Facility Name
Research Site
City
Yokohama-shi
State/Province
Kanagawa
ZIP/Postal Code
221-0802
Country
Japan
Facility Name
Research Site
City
Yokohama-shi
State/Province
Kanagawa
ZIP/Postal Code
231-0023
Country
Japan
Facility Name
Research Site
City
Yokohama-shi
State/Province
Kanagawa
ZIP/Postal Code
241-0821
Country
Japan
Facility Name
Research Site
City
Kyoto-shi
State/Province
Kyoto
ZIP/Postal Code
600-8898
Country
Japan
Facility Name
Research Site
City
Kyoto-shi
State/Province
Kyoto
ZIP/Postal Code
615-8125
Country
Japan
Facility Name
Research Site
City
Kawagoe-shi
State/Province
Saitama
ZIP/Postal Code
350-0851
Country
Japan
Facility Name
Research Site
City
Kawaguchi-shi
State/Province
Saitama
ZIP/Postal Code
332-0021
Country
Japan
Facility Name
Research site
City
Sayama-shi
State/Province
SAitama
ZIP/Postal Code
350-1305
Country
Japan
Facility Name
Research Site
City
Hachioji-shi
State/Province
Tokyo
ZIP/Postal Code
192-0918
Country
Japan
Facility Name
Research Site
City
Hachioji-shi
State/Province
Tokyo
ZIP/Postal Code
193-0811
Country
Japan
Facility Name
Research Site
City
Minato-ku
State/Province
Tokyo
ZIP/Postal Code
108-0075
Country
Japan
Facility Name
Research Site
City
Ota-ku
State/Province
Tokyo
ZIP/Postal Code
143-0015
Country
Japan
Facility Name
Research Site
City
Shinagawa-ku
State/Province
Tokyo
ZIP/Postal Code
141-0032
Country
Japan
Facility Name
Research Site
City
Toshima-ku
State/Province
Toyko
ZIP/Postal Code
171-0021
Country
Japan
Facility Name
Research Site
City
Alcala de Henares
ZIP/Postal Code
28805
Country
Spain
Facility Name
Research Site
City
Alicante
ZIP/Postal Code
03004
Country
Spain
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28009
Country
Spain
Facility Name
Research Site
City
Malaga
ZIP/Postal Code
29009
Country
Spain
Facility Name
Research Site
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Research Site
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46600
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

We'll reach out to this number within 24 hrs